{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:09:03Z","timestamp":1789520943037,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["961697"],"award-info":[{"award-number":["961697"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.intimp.2024.112437","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T23:12:51Z","timestamp":1718233971000},"page":"112437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5548-1137","authenticated-orcid":false,"given":"Rahimeh","family":"Khoshkhabar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh","family":"Hoda Alavizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Reza Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2024.112437_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca Cancer J Clin"},{"issue":"6","key":"10.1016\/j.intimp.2024.112437_b0010","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.intimp.2024.112437_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107833","article-title":"Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model","volume":"98","author":"Yazdani","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.112437_b0020","doi-asserted-by":"crossref","first-page":"102461","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2, 3-dioxygenase (IDO) inhibitors and cancer immunotherapy","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2024.112437_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.15698\/cst2020.01.210","article-title":"Kynurenine: an oncometabolite in colon cancer","volume":"4","author":"Venkateswaran","year":"2020","journal-title":"Cell Stress"},{"key":"10.1016\/j.intimp.2024.112437_b0030","doi-asserted-by":"crossref","first-page":"110841","DOI":"10.1016\/j.exger.2020.110841","article-title":"Kynurenine pathway, NAD+ synthesis, and mitochondrial function: Targeting tryptophan metabolism to promote longevity and healthspan","volume":"132","author":"Castro-Portuguez","year":"2020","journal-title":"Exp. Gerontol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112437_b0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-018-0291-4","article-title":"\u201cIndoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy,\u201d (in eng)","volume":"32","author":"Yentz","year":"2018","journal-title":"BioDrugs"},{"issue":"25","key":"10.1016\/j.intimp.2024.112437_b0040","doi-asserted-by":"crossref","first-page":"37762","DOI":"10.18632\/oncotarget.9326","article-title":"The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2024.112437_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2019.110797","article-title":"\u201cKynurenine signaling through the aryl hydrocarbon receptor: Implications for aging and healthspan,\u201d (in eng)","volume":"130","author":"Kaiser","year":"2020","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.intimp.2024.112437_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"\u201cIndoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy,\u201d (in eng)","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.intimp.2024.112437_b0055","doi-asserted-by":"crossref","first-page":"1777625","DOI":"10.1080\/2162402X.2020.1777625","article-title":"\u201cTrial watch: IDO inhibitors in cancer therapy,\u201d (in eng)","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2024.112437_b0060","first-page":"41","volume":"vol. 41:","author":"Muller","year":"2019","journal-title":"Inhibiting IDO Pathways to Treat Cancer: Lessons from the ECHO-301 Trial and beyond"},{"issue":"24","key":"10.1016\/j.intimp.2024.112437_b0065","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2024.112437_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112437_b0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/0394632017714696","article-title":"Combinatorial antitumor effects of indoleamine 2, 3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16\u2013F10 melanoma model","volume":"30","author":"Meng","year":"2017","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112437_b0080","doi-asserted-by":"crossref","first-page":"1165298","DOI":"10.3389\/fonc.2023.1165298","article-title":"\u201cIDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation,\u201d (in eng)","volume":"13","author":"Muller","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.intimp.2024.112437_b0085","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jconrel.2023.01.034","article-title":"\u201cLiposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma,\u201d (in eng)","volume":"354","author":"Jahani","year":"2023","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.intimp.2024.112437_b0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41416-019-0664-6","article-title":"The therapeutic potential of targeting tryptophan catabolism in cancer","volume":"122","author":"Opitz","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"16","key":"10.1016\/j.intimp.2024.112437_b0095","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-04-2671","article-title":"\u201cIndoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells,\u201d (in eng)","volume":"11","author":"Okamoto","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.112437_b0100","doi-asserted-by":"crossref","first-page":"594098","DOI":"10.3389\/fonc.2020.594098","article-title":"Indoleamine 2, 3-dioxygenase 1 and CD8 expression profiling revealed an immunological subtype of colon cancer with a poor prognosis","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"issue":"13","key":"10.1016\/j.intimp.2024.112437_b0105","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2, 3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid MalignanciesIDO1 Inhibitor in Advanced Solid Cancers","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.112437_b0110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/0008-5472.CAN-18-1106","article-title":"Treatment-induced tumor cell apoptosis and secondary necrosis drive tumor progression in the residual tumor microenvironment through MerTK and IDO1","volume":"79","author":"Werfel","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2024.112437_b0115","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1111\/bph.14351","article-title":"LW106, a novel inhibitor of IDO1, suppresses tumor progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in the tumor microenvironment","volume":"175","author":"Fu","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112437_b0120","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1038\/s41598-023-31007-x","article-title":"Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine","volume":"13","author":"Tahaghoghi-Hajghorbani","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2024.112437_b0125","doi-asserted-by":"crossref","first-page":"1730538","DOI":"10.1080\/2162402X.2020.1730538","article-title":"Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy","volume":"9","author":"Georganaki","year":"2020","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.intimp.2024.112437_b0130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1535-7163.MCT-09-0628","article-title":"Hydroxyamidine inhibitors of indoleamine-2, 3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors","volume":"9","author":"Koblish","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"17","key":"10.1016\/j.intimp.2024.112437_b0135","first-page":"3520","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood, the Journal of the American Society of Hematology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112437_b0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13046-021-01847-4","article-title":"What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past","volume":"40","author":"Yao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.112437_b0145","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ejps.2021.105954","article-title":"Development of a novel formulation method to prepare liposomal Epacadostat","volume":"165","author":"Tahaghoghi-Hajghorbani","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2024.112437_b0150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11912-023-01385-6","article-title":"Chemotherapy in Cutaneous Melanoma: Is There Still a Role?","volume":"25","author":"Pham","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2024.112437_b0155","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ijc.28070","article-title":"Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death","volume":"133","author":"Hodge","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2024.112437_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110214","article-title":"\u201cThe interactions of docetaxel with tumor microenvironment,\u201d (in eng)","volume":"119","author":"Gupta","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.intimp.2024.112437_b0165","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/832059","article-title":"\u201cCombination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells,\u201d (in eng)","volume":"2012","author":"Tsakalozou","year":"2012","journal-title":"Biochem Res Int"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2024.112437_b0170","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijpharm.2014.07.020","article-title":"\u201cThe influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma,\u201d (in eng)","volume":"473","author":"Alavizadeh","year":"2014","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.intimp.2024.112437_b0175","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/bj1390625","article-title":"A fluorimetric method for the determination of tryptophan in animal tissues","volume":"139","author":"Gaitonde","year":"1974","journal-title":"Biochem. J"},{"issue":"56","key":"10.1016\/j.intimp.2024.112437_b0180","doi-asserted-by":"crossref","first-page":"30814","DOI":"10.18632\/oncotarget.25720","article-title":"\u201cCell based functional assays for IDO1 inhibitor screening and characterization,\u201d (in eng)","volume":"9","author":"Richards","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2024.112437_b0185","doi-asserted-by":"crossref","unstructured":"J. P. Robinson, R. Ostafe, S. N. Iyengar, B. Rajwa, and R. Fischer, \u201cFlow Cytometry: The Next Revolution,\u201d (in eng), Cells, vol. 12, no. 14, Jul 17 2023, doi: 10.3390\/cells12141875.","DOI":"10.3390\/cells12141875"},{"issue":"1","key":"10.1016\/j.intimp.2024.112437_b0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000096906","article-title":"\u201cDecreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients,\u201d (in eng)","volume":"214","author":"Weinlich","year":"2007","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112437_b0195","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2017.07.005","volume":"146","author":"Kristeleit","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.intimp.2024.112437_b0200","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1039\/C9BM00324J","article-title":"Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy","volume":"7","author":"Qiao","year":"2019","journal-title":"Biomater. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2024.112437_b0205","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2024.112437_b0210","doi-asserted-by":"crossref","first-page":"119446","DOI":"10.1016\/j.ijpharm.2020.119446","article-title":"Co-delivery of doxorubicin and epacadostat via heparin coated pH-sensitive liposomes to suppress the lung metastasis of melanoma","volume":"584","author":"Chen","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.intimp.2024.112437_b0215","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"\u201cIndoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4,\u201d (in eng)","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2024.112437_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"18","key":"10.1016\/j.intimp.2024.112437_b0225","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.18632\/oncotarget.2357","article-title":"\u201cA first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors,\u201d (in eng)","volume":"5","author":"Soliman","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2024.112437_b0230","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.1200\/JCO.2018.36.15_suppl.9512","article-title":"Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma","volume":"vol. 36, no. 15_suppl","author":"Zakharia","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.112437_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2020.101959","article-title":"Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer","volume":"60","author":"Imran","year":"2020","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"14","key":"10.1016\/j.intimp.2024.112437_b0240","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1111\/bph.14351","article-title":"LW106, a novel indoleamine 2, 3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment","volume":"175","author":"Fu","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112437_b0245","doi-asserted-by":"crossref","first-page":"1134551","DOI":"10.3389\/fimmu.2023.1134551","article-title":"\u201cThe catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1,\u201d (in eng)","volume":"14","author":"Panfili","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2024.112437_b0250","doi-asserted-by":"crossref","unstructured":"S. Corre et al., \u201cSustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma,\u201d (in eng), Nat Commun, vol. 9, no. 1, p. 4775, Nov 14 2018.","DOI":"10.1038\/s41467-018-06951-2"},{"issue":"10","key":"10.1016\/j.intimp.2024.112437_b0255","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/ijc.33252","article-title":"\u201cThe aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells,\u201d (in eng)","volume":"147","author":"Mengoni","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.intimp.2024.112437_b0260","doi-asserted-by":"crossref","unstructured":"D. Leclerc, A. C. Staats Pires, G. J. Guillemin, and D. Gilot, \u201cDetrimental activation of AhR pathway in cancer: an overview of therapeutic strategies,\u201d Current Opinion in Immunology, vol. 70, pp. 15-26.","DOI":"10.1016\/j.coi.2020.12.003"},{"issue":"3","key":"10.1016\/j.intimp.2024.112437_b0265","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tips.2017.11.007","article-title":"\u201cTargeting the IDO1\/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities,\u201d (in eng)","volume":"39","author":"Cheong","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"22","key":"10.1016\/j.intimp.2024.112437_b0270","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1038\/s41388-021-01788-4","article-title":"C\/EBP\u03b2 promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer","volume":"40","author":"Tan","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2024.112437_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.625346","article-title":"\u201cTargeting the Aryl Hydrocarbon Receptor Signaling Pathway in Breast Cancer Development,\u201d (in eng)","volume":"12","author":"Vogel","year":"2021","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.intimp.2024.112437_b0280","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1523\/JNEUROSCI.5032-08.2009","article-title":"\u201cInterferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin,\u201d (in eng)","volume":"29","author":"O'Connor","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.intimp.2024.112437_b0285","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"\u201cRoles of IFN-\u03b3 in tumor progression and regression: a review,\u201d (in eng)","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark Res"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T15:35:33Z","timestamp":1720280133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924009585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":57,"alternative-id":["S1567576924009585"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112437","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112437"}}